Here we review the actions of FGF21 and summarize the associated clinical trials in obesity, type 2 diabetes mellitus (T2DM), and NAFLD, to help understand and promote the development of efficient treatment for metabolic diseases via targeting FGF21. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.